+1 (209) 299 5348
Abiomed Wins 2nd EUA for Impella Related to COVID-19
Abiomed has been awarded a second Emergency Use Authorization for its Impella heart pump to help treat COVID-19 patients.
Impella combined with ECMO therapy (known as ECpella) has become an important tool for physicians treating COVID-19 patients suffering from both heart and lung failure.
| https://www.mddionline.com/cardiovascular/another-one-abiomed-wins-2nd-eua-impella-related-covid-19 |
Latest News
- Latest News
- Webinars
- Suggest a Speaker
- FDA issues EUA to first next gen sequence test for COVID-19
- Illumina taps IDbyDNA for infectious disease sequencing co-marketing initiative
- IDbyDNA taps YouTube, Stemcentrx backer to develop infectious disease data platform
- How Next-Generation Sequencing Will Help Scientists in the COVID-19 Battle
- New COVID-19 Testing Supply Registry Provides a Map to Recovery
- Siemens Developing New Diagnostic for COVID-19